Comments
Loading...

Kiromic BioPharma Inc Ordinary Shares Analyst Ratings

KRBPOTC
Logo brought to you by Benzinga Data
$0.1601
At close: Mar 21, 9:13 AM EDT
$0.7400
0.58362.21%
After Hours: Mar 21, 9:13 AM EDT

Kiromic BioPharma Inc Ordinary Shares Analyst Ratings and Price Targets | OTC:KRBP | Benzinga

Kiromic BioPharma Inc Ordinary Shares Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Kiromic BioPharma Inc Ordinary Shares Corp from these most-recent analyst ratings.

Analyst Ratings for Kiromic BioPharma Inc Ordinary Shares

Buy NowGet Alert
No data available to display

FAQ

Q

What is the target price for Kiromic BioPharma Inc Ordinary Shares (KRBP) stock?

A

There is no price target for Kiromic BioPharma Inc Ordinary Shares

Q

What is the most recent analyst rating for Kiromic BioPharma Inc Ordinary Shares (KRBP)?

A

There is no analyst for Kiromic BioPharma Inc Ordinary Shares

Q

When was the last upgrade for Kiromic BioPharma Inc Ordinary Shares (KRBP)?

A

There is no last upgrade for Kiromic BioPharma Inc Ordinary Shares

Q

When was the last downgrade for Kiromic BioPharma Inc Ordinary Shares (KRBP)?

A

There is no last downgrade for Kiromic BioPharma Inc Ordinary Shares.

Q

When is the next analyst rating going to be posted or updated for Kiromic BioPharma Inc Ordinary Shares (KRBP)?

A

There is no next analyst rating for Kiromic BioPharma Inc Ordinary Shares.

Q

Is the Analyst Rating Kiromic BioPharma Inc Ordinary Shares (KRBP) correct?

A

There is no next analyst rating for Kiromic BioPharma Inc Ordinary Shares.

Browse analyst ratings and price targets on all stocks.